Eden Biodesign Ltd. (Liverpool, UK) and iQur Ltd. (Southampton, UK) have entered into an agreement to develop iQur’s tandem core vaccine for hepatitis A and B.
Eden Biodesign Ltd. (Liverpool, UK) and iQur Ltd. (Southampton, UK) have entered into an agreement to develop iQur’s tandem core vaccine for hepatitis A and B. Eden will develop a unique biomanufacturing process to achieve optimal product quality in line with cost of goods parameters before proceeding with clinical cGMP manufacture. The project to develop the vaccine also will involve a consortium of collaborators, including Arecor (Bedfordshire, UK), who will apply its proprietary protein stabilization technology, and Mologic (Bedford, UK), who will develop its novel yeast expression systems.
Research conducted by iQur has suggested that its novel vaccine platform, based on the HBV core protein, can carry antigens specific for both hepatitis A and B simultaneously. Because the construct is highly immunogenic, it should dramatically increase vaccine efficiency and reduce the current need for booster vaccinations, said Eden in a press release. The vaccine platform will also serve as a proof-of-concept for other combination vaccines.
Eden release (PDF)
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.